Literature DB >> 25782745

Design strategies to address kinetics of drug binding and residence time.

Kevin P Cusack1, Ying Wang2, Michael Z Hoemann3, Jasmina Marjanovic2, Roland G Heym4, Anil Vasudevan2.   

Abstract

The kinetics of drug binding and drug residence time are recognized to be important in the clinical effectiveness of drug candidates. In most cases a long residence time of the drug-target complex results in an extended duration of pharmacodynamic activity, even when systemic concentrations of drug have been notably reduced through elimination routes. Hence, if selective for target, long residence times can increase the duration of drug efficacy in vivo and can significantly diminish the potential for off-target-mediated toxicities. Furthermore, a compound with a slower dissociation rate may allow a reduced dosing schedule relative to a compound with a rapid dissociation rate. Factors contributing to long residence time that could be useful to medicinal chemists in the prospective design of compounds with long residence times will be discussed in this perspective. Particular emphasis will be on case studies highlighting how kinetics can be measured, modulated based on supporting structure kinetic relationships and whether these effects are translatable into man.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Design; Kinetics; Modeling; Residence time; Structure kinetic relationship (SKR)

Mesh:

Substances:

Year:  2015        PMID: 25782745     DOI: 10.1016/j.bmcl.2015.02.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

Review 1.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 2.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 3.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

4.  Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.

Authors:  Lauren A Spagnuolo; Sandra Eltschkner; Weixuan Yu; Fereidoon Daryaee; Shabnam Davoodi; Susan E Knudson; Eleanor K H Allen; Jonathan Merino; Annica Pschibul; Ben Moree; Neil Thivalapill; James J Truglio; Joshua Salafsky; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal:  J Am Chem Soc       Date:  2017-02-22       Impact factor: 15.419

Review 5.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

Review 6.  Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling.

Authors:  M Bernetti; A Cavalli; L Mollica
Journal:  Medchemcomm       Date:  2017-01-30       Impact factor: 3.597

7.  Binding Thermodynamics and Kinetics Calculations Using Chemical Host and Guest: A Comprehensive Picture of Molecular Recognition.

Authors:  Zhiye Tang; Chia-En A Chang
Journal:  J Chem Theory Comput       Date:  2017-12-14       Impact factor: 6.006

Review 8.  Biophysics in drug discovery: impact, challenges and opportunities.

Authors:  Jean-Paul Renaud; Chun-Wa Chung; U Helena Danielson; Ursula Egner; Michael Hennig; Roderick E Hubbard; Herbert Nar
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

9.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

10.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.